Halozyme Therapeutics (HALO)
NASDAQ: HALO · Biotechnology · San Diego, CA
Our rating: Positive
Positive reaffirmed at $103.63, moderate conviction, November 6, 2026.
Breaks if: The positive lean inverts if trailing twelve-month revenue growth decelerates below 15% — a signal that partner drug attrition or pricing pressure is biting the royalty line — or if free cash flow margin falls below 35% for two consecutive reported quarters, indicating that the platform's cash-conversion edge is narrowing rather than durable. Either condition within the next twelve months would force a reassessment toward Neutral or Cautious.
Key figures
| Market value | $10.4B |
|---|---|
| Revenue, last 12 months | $1.8B |
| Net income, last 12 months | $485M |
| Free cash flow, last 12 months | $886M |
| Price to earnings | 21.5× |
| Free cash flow yield | 8.5% |
| Dividend yield | 0.0% |
| Operating margin | 37.4% |
| Return on equity | 216.4% |
| Beta to the S&P 500 | 0.62 |
| Volatility, annualized | 43.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $493M | 39.2% | $2.01 | $255M |
| June 30, 2026 | $481M | 47.7% | $1.90 | $237M |
| March 31, 2026 | $377M | 42.2% | $1.22 | $176M |
| December 31, 2025 | $452M | 51.6% | $-1.12 | $218M |
| September 30, 2025 | $354M | 22.1% | $1.43 | $176M |
| June 30, 2025 | $326M | 40.8% | $1.33 | $98M |
| March 31, 2025 | $265M | 35.2% | $0.93 | $153M |
| December 31, 2024 | $298M | 29.5% | $1.06 | $175M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.66B: Claude 42%, Gemini 75%, Mistral 42%
- Diluted earnings per share are above zero: Claude 88%, Gemini 95%, Mistral 95%
- Free cash flow for the quarter is at least $0.22B: Claude 62%, Gemini 90%, Mistral 80%
28 ledger entries and 66 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.